{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:01:14Z","timestamp":1761897674418,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41375-022-01633-x","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:03:12Z","timestamp":1656360192000},"page":"2136-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-077X","authenticated-orcid":false,"given":"Natalia","family":"Neparidze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-8032","authenticated-orcid":false,"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-9249","authenticated-orcid":false,"given":"Amy J.","family":"Davidoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"1633_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/CCI.20.00134","volume":"4","author":"D Patt","year":"2020","unstructured":"Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform. 2020;4:1059\u201371.","journal-title":"JCO Clin Cancer Inform"},{"key":"1633_CR2","first-page":"1","volume":"17","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematol. 2020;17:1\u20137.","journal-title":"Acta Haematol"},{"key":"1633_CR3","first-page":"1","volume":"22","author":"E Terpos","year":"2020","unstructured":"Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ioannis NS, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;22:1\u201312.","journal-title":"Leukemia."},{"key":"1633_CR4","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S2352-3026(20)30124-1","volume":"7","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematol. 2020;7:e435\u2013e437.","journal-title":"Lancet Haematol."},{"key":"1633_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjh.16815","volume":"190","author":"CL Freeman","year":"2020","unstructured":"Freeman CL, Mikhael J. Covid-19 and Myeloma: what are the implications for now and in the future? Br J Haematol. 2020;190:173\u20138.","journal-title":"Br J Haematol"},{"key":"1633_CR6","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","volume":"34","author":"E Terpos","year":"2020","unstructured":"Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ioannis NS, et al. Management of patients with multiple myeloma in the era of COVID\u201019 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34:2000\u201311.","journal-title":"Leukemia."},{"unstructured":"British Society of Blood and Marrow Transplantation and Cellular Therapy. BSBMTCT recommendations for the management of adult patients and allogeneic donors during the COVID19 (causative agent the SARS\u2010CoV\u20102 virus) outbreak. BMTCT Guidelines. 2020.","key":"1633_CR7"},{"doi-asserted-by":"publisher","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. MedRxiv. https:\/\/doi.org\/10.1101\/2020.03.16.20037143.","key":"1633_CR8","DOI":"10.1101\/2020.03.16.20037143"},{"key":"1633_CR9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1200\/JOP.2017.024224","volume":"13","author":"AP Abernethy","year":"2017","unstructured":"Abernethy AP, Gippetti J, Parulkar R, Revol C. Use of electronic health record data for quality reporting. J Oncol Pract. 2017;13:530\u20134.","journal-title":"J Oncol Pract."},{"key":"1633_CR10","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1002\/cncr.32383","volume":"125","author":"S Khozin","year":"2019","unstructured":"Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, et al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer 2019;125:4019\u201332.","journal-title":"Cancer"},{"doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 20;136:936\u201345.","key":"1633_CR11","DOI":"10.1182\/blood.2020005288"},{"key":"1633_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2021.07.002","volume":"160","author":"S Bhalla","year":"2021","unstructured":"Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, et al. Care disruptions among patients with lung cancer: a COVID-19 and cancer outcomes study. Lung Cancer. 2021;160:78\u201383.","journal-title":"Lung Cancer"},{"key":"1633_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/GO.20.00639","volume":"7","author":"R Riera","year":"2021","unstructured":"Riera R, Bagattini \u00c2M, Pacheco RL, Pachito DV, Roitberg F, Ilbavi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. JCO Glob Oncol 2021;7:311\u201323.","journal-title":"JCO Glob Oncol"},{"key":"1633_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","volume":"21","author":"C Maringe","year":"2020","unstructured":"Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023\u201334.","journal-title":"Lancet Oncol"},{"key":"1633_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/jnci\/djab225","volume":"114","author":"RB Parikh","year":"2022","unstructured":"Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, et al. Impact of the COVID-19 pandemic on treatment patterns for patients with metastatic solid cancer in the United States. J Natl Cancer Inst. 2022;114:571\u20138. Apr 11","journal-title":"J Natl Cancer Inst"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01633-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01633-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01633-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:10:53Z","timestamp":1659337853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01633-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1633"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01633-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NN receives research funding from Janssen and Glaxo-Smith-Kline and has received honoraria from Eidos Therapeutics. NAP consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation pharmaceuticals, Cogent biosciences, AbbVie. NAP received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, Kartos Therapeutics. RMS consulted for and received honoraria from Bristol-Myers Squibb. XM received research funding (institutional) from Celgene\/Bristol-Myers Squibb and consults for Bristol-Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}